Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Background: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to investigate the effectiveness and safety of the D...

Full description

Bibliographic Details
Main Authors: Rodolfo Sacco, Vincenzo Messina, Umberto Vespasiani Gentilucci, Luigi Elio Adinolfi, Antonio Ascione, Giorgio Barbarini, Angelo Barlattani, Giuseppe Cariti, Raffaele Cozzolongo, Basilio Fimiani, Ruggiero Francavilla, Caterina Furlan, Giovanni Garrucciu, Vincenzo Iovinella, Luca Rinaldi, Massimo Marignani, Paola Begini, Valeria Pace Palitti, Adriano M Pellicelli, Gaetano Scifo, Antonio Facciorusso, Luca Giacomelli, Aashni Shah, Gaetano Bertino, Serena Perazzo, Giampaolo Bresci, Antonio Izzi
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-12-01
Series:Drugs in Context
Subjects:
daclatasvir
direct-acting antivirals
hcv ns5a inhibitors
hcv replication complex
ribavirin
sofosbuvir
Online Access:https://www.drugsincontext.com/sustained-virological-response-in-patients-with-hcv-treated-with-daclatasvir-sofosbuvir-with-or-without-ribavirin-a-large-field-practice-study

Similar Items

Similar Items